Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the "Company") will present results from six ...

BriaCell's Phase 2 study also achieved a Clinical Benefit Rate (CBR) of 61%, outperforming ASCENT (40%) and TROPiCS-02 (34%), ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

Equity Insider News Commentary ? With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is increasingly being shaped not by public institutions, but by ...

The WHO's new pandemic agreement raises concerns about national sovereignty and potential global surveillance during future ...

Developed over five phases, BioMed Realty’s Gateway of Pacific campus consists of 2.2 million square feet of state-of-the-art ...

H.H. Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, and Minister of Defence, stated that empowering a new generation of Emiratis with future-ready ...

Crescita Therapeutics Inc. ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities, today announced ...

Regeneron Pharmaceuticals, Inc. REGN announced encouraging initial results from two cohorts of the early-stage study on ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

Comfort Systems gains from data center demand, tech investment, and policy tailwinds, with strong growth and M&A execution.